In the latest trading session, 0.44 million ORIC Pharmaceuticals Inc (NASDAQ:ORIC) shares changed hands as the company’s beta touched 1.11. With the company’s most recent per share price at $9.13 changing hands around $0.42 or 4.82% at last look, the market valuation stands at $644.03M. ORIC’s current price is a discount, trading about -82.37% off its 52-week high of $16.65. The share price had its 52-week low at $5.34, which suggests the last value was 41.51% up since then. When we look at ORIC Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.35 million shares, with the 3-month average coming to 442.20K.
Analysts gave the ORIC Pharmaceuticals Inc (ORIC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.10. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ORIC as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. ORIC Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.49.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ORIC Pharmaceuticals Inc (NASDAQ:ORIC) trade information
Instantly ORIC is in green as seen in intraday trades today. With action -5.39%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -0.76%, with the 5-day performance at -5.39% in the red. However, in the 30-day time frame, ORIC Pharmaceuticals Inc (NASDAQ:ORIC) is -15.07% down. Looking at the short shares, we see there were 12.26 million shares sold at short interest cover period of 23.39 days.
The consensus price target for the stock as assigned by Wall Street analysts is 20, meaning bulls need an upside of 54.35% from its recent market value. According to analyst projections, ORIC’s forecast low is 7 with 21 as the target high. To hit the forecast high, the stock’s price needs a -130.01% plunge from its current level, while the stock would need to tank 23.33% for it to hit the projected low.
ORIC Pharmaceuticals Inc (ORIC) estimates and forecasts
Data shows that the ORIC Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 13.00% over the past 6 months, a 8.16% in annual growth rate that is considerably lower than the industry average of 17.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -22.33%. The 2024 estimates are for ORIC Pharmaceuticals Inc earnings to increase by 4.56%.
ORIC Dividends
ORIC Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2024-Nov-04.
ORIC Pharmaceuticals Inc (NASDAQ:ORIC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 9.13% of ORIC Pharmaceuticals Inc shares while 99.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 109.05%. There are 99.09% institutions holding the ORIC Pharmaceuticals Inc stock share, with NEXTECH INVEST LTD. the top institutional holder. As of 2024-06-30, the company held 7.8482% of the shares, roughly 5.29 million ORIC shares worth $37.37 million.
FMR LLC holds the second largest percentage of outstanding shares, with 7.3057% or 4.92 million shares worth $34.79 million as of 2024-06-30.
